MRTX1133 is primarily used in the field of cancer research and treatment. It is a potent and selective inhibitor targeting specific mutations in the KRAS protein, particularly the KRAS G12D mutation, which is commonly found in various cancers such as pancreatic, colorectal, and lung cancers. By inhibiting this mutation, MRTX1133 helps to block the signaling pathways that promote tumor growth and survival. This makes it a promising candidate for developing targeted therapies for patients with KRAS G12D-driven cancers. Its application is currently focused on preclinical and clinical studies to evaluate its efficacy, safety, and potential as a therapeutic agent in oncology.